Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study

DOI record: { "DOI": "10.1007/s40121-024-00971-w", "ISSN": [ "2193-8229", "2193-6382" ], "URL": "http://dx.doi.org/10.1007/s40121-024-00971-w", "alternative-id": [ "971" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "15 February 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "28 March 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "12 April 2024" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of Interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "Soyoon Hwang, Nan Young Lee, Eunkyung Nam, Yu Kyung Kim, Shin-Woo Kim, Hyun-Ha Chang, Yoonjung Kim, Sohyun Bae, Juhwan Jeong, Jae-Ho Shin, Guehwan Jang, Changhee Lee, and Ki Tae Kwon declare no conflicts of interest." }, { "group": { "label": "Ethical Approval and Informed Consent", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "This study was approved by the Daegu Joint Institutional Review Board, and the requirement for official written informed consent was waived (DGIRB 2021-10-002), given the retrospective nature of the study (using EMR and residual samples)." } ], "author": [ { "ORCID": "http://orcid.org/0000-0003-3618-174X", "affiliation": [], "authenticated-orcid": false, "family": "Hwang", "given": "Soyoon", "sequence": "first" }, { "ORCID": "http://orcid.org/0000-0002-3381-1382", "affiliation": [], "authenticated-orcid": false, "family": "Lee", "given": "Nan Young", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-9845-3563", "affiliation": [], "authenticated-orcid": false, "family": "Nam", "given": "Eunkyung", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-4699-8502", "affiliation": [], "authenticated-orcid": false, "family": "Kim", "given": "Yu Kyung", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-3755-8249", "affiliation": [], "authenticated-orcid": false, "family": "Kim", "given": "Shin-Woo", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-9405-2121", "affiliation": [], "authenticated-orcid": false, "family": "Chang", "given": "Hyun-Ha", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-7454-4014", "affiliation": [], "authenticated-orcid": false, "family": "Kim", "given": "Yoonjung", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-0206-7108", "affiliation": [], "authenticated-orcid": false, "family": "Bae", "given": "Sohyun", "sequence": "additional" }, { "ORCID": "http://orcid.org/0009-0003-5004-6998", "affiliation": [], "authenticated-orcid": false, "family": "Jeong", "given": "Juhwan", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-6450-9787", "affiliation": [], "authenticated-orcid": false, "family": "Shin", "given": "Jae-Ho", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-3108-8087", "affiliation": [], "authenticated-orcid": false, "family": "Jang", "given": "Guehwan", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-5930-5461", "affiliation": [], "authenticated-orcid": false, "family": "Lee", "given": "Changhee", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-4666-0672", "affiliation": [], "authenticated-orcid": false, "family": "Kwon", "given": "Ki Tae", "sequence": "additional" } ], "container-title": "Infectious Diseases and Therapy", "container-title-short": "Infect Dis Ther", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2024, 4, 12 ] ], "date-time": "2024-04-12T13:01:45Z", "timestamp": 1712926905000 }, "deposited": { "date-parts": [ [ 2024, 4, 12 ] ], "date-time": "2024-04-12T13:31:27Z", "timestamp": 1712928687000 }, "funder": [ { "DOI": "10.13039/100018592", "doi-asserted-by": "publisher", "name": "Celltrion" } ], "indexed": { "date-parts": [ [ 2024, 4, 13 ] ], "date-time": "2024-04-13T00:36:43Z", "timestamp": 1712968603316 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 4, 12 ] ] }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 4, 12 ] ], "date-time": "2024-04-12T00:00:00Z", "timestamp": 1712880000000 } }, { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 4, 12 ] ], "date-time": "2024-04-12T00:00:00Z", "timestamp": 1712880000000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s40121-024-00971-w.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s40121-024-00971-w/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s40121-024-00971-w.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1007", "published": { "date-parts": [ [ 2024, 4, 12 ] ] }, "published-online": { "date-parts": [ [ 2024, 4, 12 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1016/j.bsheal.2021.02.001", "author": "P Deb", "doi-asserted-by": "publisher", "first-page": "87", "issue": "2", "journal-title": "Biosaf Health", "key": "971_CR1", "unstructured": "Deb P, Molla MMA, Saif-Ur-Rahman K. An update to monoclonal antibody as therapeutic option against COVID-19. Biosaf Health. 2021;3(2):87–91.", "volume": "3", "year": "2021" }, { "DOI": "10.1038/s41467-020-20602-5", "author": "C Kim", "doi-asserted-by": "publisher", "first-page": "288", "issue": "1", "journal-title": "Nat Commun", "key": "971_CR2", "unstructured": "Kim C, Ryu D-K, Lee J, et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun. 2021;12(1):288.", "volume": "12", "year": "2021" }, { "DOI": "10.1007/s40265-021-01626-7", "author": "YY Syed", "doi-asserted-by": "publisher", "first-page": "2133", "issue": "18", "journal-title": "Drugs", "key": "971_CR3", "unstructured": "Syed YY. Regdanvimab: First approval. Drugs. 2021;81(18):2133–7.", "volume": "81", "year": "2021" }, { "DOI": "10.1093/ofid/ofac053", "author": "A Streinu-Cercel", "doi-asserted-by": "publisher", "first-page": "ofac053", "journal-title": "Open Forum Infect Dis", "key": "971_CR4", "unstructured": "Streinu-Cercel A, Săndulescu O, Preotescu L-L, et al. Efficacy and safety of regdanvimab (CT-P59): a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate coronavirus disease 2019. Open Forum Infect Dis. 2022;9:ofac053.", "volume": "9", "year": "2022" }, { "DOI": "10.1016/j.envres.2021.112240", "author": "Y Zhao", "doi-asserted-by": "publisher", "journal-title": "Environ Res", "key": "971_CR5", "unstructured": "Zhao Y, Huang J, Zhang L, Chen S, Gao J, Jiao H. The global transmission of new coronavirus variants. Environ Res. 2022;206: 112240.", "volume": "206", "year": "2022" }, { "DOI": "10.1146/annurev-med-042921-020956", "author": "JL Jacobs", "doi-asserted-by": "publisher", "first-page": "31", "journal-title": "Ann Rev Med", "key": "971_CR6", "unstructured": "Jacobs JL, Haidar G, Mellors JW. COVID-19: challenges of viral variants. Ann Rev Med. 2023;74:31–53.", "volume": "74", "year": "2023" }, { "DOI": "10.1038/s41586-021-04389-z", "author": "D Planas", "doi-asserted-by": "publisher", "first-page": "671", "issue": "7898", "journal-title": "Nature", "key": "971_CR7", "unstructured": "Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 omicron to antibody neutralization. Nature. 2022;602(7898):671–5.", "volume": "602", "year": "2022" }, { "DOI": "10.1016/j.bbrc.2021.09.023", "author": "D-K Ryu", "doi-asserted-by": "publisher", "first-page": "91", "journal-title": "Biochem Biophys Res Commun", "key": "971_CR8", "unstructured": "Ryu D-K, Kang B, Noh H, et al. The in vitro and in vivo efficacy of CT-P59 against gamma, delta and its associated variants of SARS-CoV-2. Biochem Biophys Res Commun. 2021;578:91–6.", "volume": "578", "year": "2021" }, { "DOI": "10.1016/j.ijid.2022.12.035", "author": "YR Jang", "doi-asserted-by": "publisher", "first-page": "94", "journal-title": "Int J Infect Dis", "key": "971_CR9", "unstructured": "Jang YR, Oh YJ, Kim JY. Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the delta variant. Int J Infect Dis. 2023;130:94–100.", "volume": "130", "year": "2023" }, { "DOI": "10.3947/ic.2022.0103", "author": "YG Kwak", "doi-asserted-by": "publisher", "first-page": "781", "issue": "4", "journal-title": "Infect Chemother", "key": "971_CR10", "unstructured": "Kwak YG, Song JE, Kang J, et al. Use of the monoclonal antibody regdanvimab to treat patients hospitalized with COVID-19: real-world data during the delta variant predominance. Infect Chemother. 2022;54(4):781.", "volume": "54", "year": "2022" }, { "DOI": "10.3389/fcimb.2023.1192512", "author": "H Kim", "doi-asserted-by": "publisher", "first-page": "1192512", "journal-title": "Front Cell Infect Microbiol", "key": "971_CR11", "unstructured": "Kim H, Jang YR, Lee JY, et al. Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study. Front Cell Infect Microbiol. 2023;13:1192512.", "volume": "13", "year": "2023" }, { "DOI": "10.15585/mmwr.mm7112e1", "author": "MW Tenforde", "doi-asserted-by": "publisher", "first-page": "459", "issue": "12", "journal-title": "Morb Mortal Wkly Rep", "key": "971_CR12", "unstructured": "Tenforde MW, Self WH, Gaglani M, et al. Effectiveness of mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death—United States, March 2021–January 2022. Morb Mortal Wkly Rep. 2022;71(12):459.", "volume": "71", "year": "2022" }, { "DOI": "10.3390/vaccines10030430", "author": "S Kodera", "doi-asserted-by": "publisher", "first-page": "430", "issue": "3", "journal-title": "Vaccines", "key": "971_CR13", "unstructured": "Kodera S, Rashed EA, Hirata A. Estimation of real-world vaccination effectiveness of mRNA COVID-19 vaccines against delta and omicron variants in Japan. Vaccines. 2022;10(3):430.", "volume": "10", "year": "2022" }, { "DOI": "10.1016/j.mayocp.2021.12.002", "author": "JC O’Horo", "doi-asserted-by": "publisher", "first-page": "327", "journal-title": "Mayo Clin Proc", "key": "971_CR14", "unstructured": "O’Horo JC, Challener DW, Speicher L, et al. Effectiveness of monoclonal antibodies in preventing severe COVID-19 with emergence of the delta variant. Mayo Clin Proc. 2022;97:327–32.", "volume": "97", "year": "2022" }, { "DOI": "10.1093/cid/ciac239", "author": "S Park", "doi-asserted-by": "publisher", "first-page": "e27", "issue": "1", "journal-title": "Clin Infect Dis", "key": "971_CR15", "unstructured": "Park S, Lim SY, Kim JY, et al. Clinical and virological characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.617.2 (delta) variant: a prospective cohort study. Clin Infect Dis. 2022;75(1):e27–34.", "volume": "75", "year": "2022" }, { "key": "971_CR16", "unstructured": "National Institutes of Health. National Institutes of Health COVID-19 treatment guidelines. Therapeutic management of nonhospitalized adults with COVID. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/. Accessed 2 Nov 2023." }, { "DOI": "10.3947/ic.2022.0011", "author": "CM Lee", "doi-asserted-by": "publisher", "first-page": "258", "issue": "2", "journal-title": "Infect Chemother", "key": "971_CR17", "unstructured": "Lee CM, Park S-W, Lee E. Early oxygen requirement in patients with wild-to-moderate COVID-19 who received regdanvimab after delta-variant outbreak. Infect Chemother. 2022;54(2):258.", "volume": "54", "year": "2022" }, { "DOI": "10.1002/oby.23172", "author": "BG Tchang", "doi-asserted-by": "publisher", "first-page": "971", "issue": "6", "journal-title": "Obesity", "key": "971_CR18", "unstructured": "Tchang BG, Askin G, Sahagun A, et al. The independent risk of obesity and diabetes and their interaction in COVID-19: a retrospective cohort study. Obesity. 2021;29(6):971–5.", "volume": "29", "year": "2021" }, { "DOI": "10.1016/j.ejim.2021.12.024", "author": "M Holland", "doi-asserted-by": "publisher", "first-page": "15", "journal-title": "Eur J Intern Med", "key": "971_CR19", "unstructured": "Holland M, Kellett J. A systematic review of the discrimination and absolute mortality predicted by the National Early Warning Scores according to different cut-off values and prediction windows. Eur J Intern Med. 2022;98:15–26.", "volume": "98", "year": "2022" }, { "DOI": "10.1097/MEJ.0000000000000589", "author": "DJ Silcock", "doi-asserted-by": "publisher", "first-page": "433", "issue": "6", "journal-title": "Eur J Emerg Med", "key": "971_CR20", "unstructured": "Silcock DJ, Corfield AR, Staines H, Rooney KD. Superior performance of National Early Warning Score compared with quick Sepsis-related Organ Failure Assessment Score in predicting adverse outcomes: a retrospective observational study of patients in the prehospital setting. Eur J Emerg Med. 2019;26(6):433–9.", "volume": "26", "year": "2019" }, { "author": "S Alexandar", "first-page": "7", "issue": "83–85", "journal-title": "Int J Pharmacol Clin Res (IJPCR)", "key": "971_CR21", "unstructured": "Alexandar S, Ravisankar M, Kumar RS, Jakkan K. A comprehensive review on Covid-19 delta variant. Int J Pharmacol Clin Res (IJPCR). 2021;5(83–85):7.", "volume": "5", "year": "2021" }, { "DOI": "10.1016/S1473-3099(21)00475-8", "author": "KA Twohig", "doi-asserted-by": "publisher", "first-page": "35", "issue": "1", "journal-title": "Lancet Infect Dis", "key": "971_CR22", "unstructured": "Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22(1):35–42.", "volume": "22", "year": "2022" }, { "DOI": "10.1101/2021.09.03.21263091", "doi-asserted-by": "crossref", "key": "971_CR23", "unstructured": "Khedar RS, Mittal K, Ambaliya HC, et al. Greater Covid-19 severity and mortality in hospitalized patients in second (delta variant) wave compared to the first: single centre prospective study in India. medRxiv. 2021:2021.09. 03.21263091." }, { "DOI": "10.1038/s41598-022-23312-8", "author": "A Zali", "doi-asserted-by": "publisher", "first-page": "18918", "issue": "1", "journal-title": "Sci Rep", "key": "971_CR24", "unstructured": "Zali A, Khodadoost M, Gholamzadeh S, et al. Mortality among hospitalized COVID-19 patients during surges of SARS-CoV-2 alpha (B. 1.1. 7) and delta (B. 1. 617. 2) variants. Sci Rep. 2022;12(1):18918.", "volume": "12", "year": "2022" }, { "DOI": "10.3390/v13040628", "author": "AC Hurt", "doi-asserted-by": "publisher", "first-page": "628", "issue": "4", "journal-title": "Viruses", "key": "971_CR25", "unstructured": "Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for COVID-19. Viruses. 2021;13(4):628.", "volume": "13", "year": "2021" }, { "DOI": "10.1038/s41598-022-08559-5", "author": "F Touret", "doi-asserted-by": "publisher", "first-page": "4683", "issue": "1", "journal-title": "Sci Rep", "key": "971_CR26", "unstructured": "Touret F, Baronti C, Bouzidi HS, de Lamballerie X. In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B. 1.1. 529 529 isolate. Sci Rep. 2022;12(1):4683.", "volume": "12", "year": "2022" }, { "DOI": "10.1016/j.chom.2020.11.007", "author": "AJ Greaney", "doi-asserted-by": "publisher", "first-page": "44", "issue": "1", "journal-title": "Cell Host Microbe", "key": "971_CR27", "unstructured": "Greaney AJ, Starr TN, Gilchuk P, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2021;29(1):44-57.e9.", "volume": "29", "year": "2021" }, { "DOI": "10.1101/2021.12.14.21267772", "doi-asserted-by": "crossref", "key": "971_CR28", "unstructured": "Aggarwal A, Stella AO, Walker G, et al. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv: 2021-12 (2021)" } ], "reference-count": 28, "references-count": 28, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s40121-024-00971-w" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Infectious Diseases", "Microbiology (medical)" ], "subtitle": [], "title": "Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy" }